Jacob Robert Bledsoe, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lymphoma | 4 | 2024 | 1899 | 1.530 |
Why?
|
Plasma Cells | 3 | 2021 | 597 | 1.070 |
Why?
|
Immunoglobulin G | 6 | 2024 | 4533 | 1.040 |
Why?
|
Asbestosis | 2 | 2015 | 81 | 0.960 |
Why?
|
Torque teno virus | 1 | 2024 | 13 | 0.930 |
Why?
|
Carcinoma, Signet Ring Cell | 2 | 2020 | 82 | 0.820 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2024 | 251 | 0.810 |
Why?
|
Bone Marrow Diseases | 1 | 2023 | 233 | 0.750 |
Why?
|
Anemia, Aplastic | 1 | 2023 | 230 | 0.750 |
Why?
|
Pulmonary Fibrosis | 2 | 2015 | 505 | 0.720 |
Why?
|
Biliary Tract | 1 | 2021 | 135 | 0.710 |
Why?
|
Frozen Sections | 1 | 2020 | 153 | 0.660 |
Why?
|
Neutropenia | 1 | 2024 | 885 | 0.650 |
Why?
|
Anal Canal | 1 | 2021 | 374 | 0.610 |
Why?
|
Staining and Labeling | 2 | 2021 | 1081 | 0.580 |
Why?
|
Neoplasms, Plasma Cell | 1 | 2017 | 39 | 0.570 |
Why?
|
Myelodysplastic Syndromes | 3 | 2024 | 1394 | 0.570 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2021 | 339 | 0.560 |
Why?
|
Anus Neoplasms | 1 | 2021 | 329 | 0.560 |
Why?
|
Myeloproliferative Disorders | 1 | 2023 | 611 | 0.560 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2024 | 1608 | 0.510 |
Why?
|
Immunophenotyping | 2 | 2021 | 1865 | 0.510 |
Why?
|
Immune System Diseases | 1 | 2017 | 254 | 0.500 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2021 | 4020 | 0.500 |
Why?
|
Interferon Regulatory Factors | 1 | 2016 | 261 | 0.480 |
Why?
|
Papillomavirus Infections | 3 | 2021 | 1611 | 0.480 |
Why?
|
Cholangiocarcinoma | 2 | 2021 | 552 | 0.460 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2015 | 296 | 0.450 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2020 | 1405 | 0.440 |
Why?
|
Mediastinal Neoplasms | 1 | 2016 | 401 | 0.440 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2024 | 2057 | 0.420 |
Why?
|
Pancreatitis, Chronic | 1 | 2015 | 288 | 0.400 |
Why?
|
Immunohistochemistry | 5 | 2023 | 11069 | 0.360 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2917 | 0.350 |
Why?
|
Bile Duct Neoplasms | 1 | 2015 | 605 | 0.340 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 1453 | 0.340 |
Why?
|
Carcinoma | 1 | 2021 | 2327 | 0.330 |
Why?
|
Diagnostic Errors | 3 | 2021 | 1265 | 0.330 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12043 | 0.320 |
Why?
|
Diagnosis, Differential | 7 | 2024 | 12966 | 0.310 |
Why?
|
Lymph Nodes | 4 | 2024 | 3461 | 0.300 |
Why?
|
Smoking | 2 | 2015 | 9050 | 0.300 |
Why?
|
Biopsy, Fine-Needle | 1 | 2012 | 1118 | 0.280 |
Why?
|
Lung | 2 | 2015 | 9998 | 0.260 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2238 | 0.260 |
Why?
|
Mutation | 7 | 2024 | 30016 | 0.250 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 1551 | 0.230 |
Why?
|
Histiocytic Sarcoma | 1 | 2024 | 40 | 0.230 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2015 | 1727 | 0.230 |
Why?
|
Lymphocyte Transfusion | 1 | 2024 | 232 | 0.220 |
Why?
|
Adrenoleukodystrophy | 1 | 2024 | 143 | 0.200 |
Why?
|
Primary Myelofibrosis | 1 | 2024 | 209 | 0.200 |
Why?
|
Humans | 41 | 2024 | 760617 | 0.200 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20556 | 0.200 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 226 | 0.190 |
Why?
|
Adenoma | 1 | 2012 | 2159 | 0.190 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6340 | 0.190 |
Why?
|
Lentivirus | 1 | 2024 | 507 | 0.190 |
Why?
|
Middle Aged | 18 | 2024 | 220584 | 0.190 |
Why?
|
Hepatic Stellate Cells | 1 | 2022 | 119 | 0.190 |
Why?
|
Thymoma | 1 | 2023 | 188 | 0.190 |
Why?
|
Lipids | 1 | 2012 | 3332 | 0.190 |
Why?
|
Synaptophysin | 1 | 2021 | 139 | 0.190 |
Why?
|
DNA Mutational Analysis | 3 | 2021 | 4110 | 0.180 |
Why?
|
Genes, Immunoglobulin Heavy Chain | 1 | 2020 | 57 | 0.180 |
Why?
|
Chromogranins | 1 | 2021 | 160 | 0.180 |
Why?
|
Thymus Neoplasms | 1 | 2023 | 274 | 0.170 |
Why?
|
Aged | 15 | 2021 | 169042 | 0.170 |
Why?
|
Lung Neoplasms | 2 | 2015 | 13382 | 0.170 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2024 | 3634 | 0.170 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 382 | 0.170 |
Why?
|
Fanconi Anemia | 1 | 2022 | 324 | 0.170 |
Why?
|
Receptors, CXCR4 | 1 | 2024 | 727 | 0.170 |
Why?
|
Kidney Pelvis | 1 | 2020 | 186 | 0.160 |
Why?
|
Ampulla of Vater | 1 | 2020 | 149 | 0.160 |
Why?
|
Germ Cells | 1 | 2023 | 634 | 0.160 |
Why?
|
Aged, 80 and over | 8 | 2021 | 58894 | 0.160 |
Why?
|
Pelvic Neoplasms | 1 | 2021 | 247 | 0.160 |
Why?
|
Human papillomavirus 16 | 1 | 2021 | 267 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2332 | 0.160 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15251 | 0.160 |
Why?
|
Antibodies, Bispecific | 1 | 2021 | 196 | 0.160 |
Why?
|
Male | 22 | 2024 | 360358 | 0.160 |
Why?
|
Telepathology | 1 | 2018 | 77 | 0.150 |
Why?
|
Colorectal Neoplasms | 2 | 2016 | 6925 | 0.150 |
Why?
|
Female | 21 | 2024 | 392148 | 0.150 |
Why?
|
Dacryocystitis | 1 | 2018 | 68 | 0.150 |
Why?
|
Liver Transplantation | 2 | 2020 | 2329 | 0.150 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11116 | 0.140 |
Why?
|
Pancreatic Neoplasms | 1 | 2015 | 5367 | 0.140 |
Why?
|
Adult | 13 | 2024 | 220969 | 0.140 |
Why?
|
DNA Methylation | 2 | 2024 | 4391 | 0.140 |
Why?
|
Barrett Esophagus | 1 | 2020 | 492 | 0.140 |
Why?
|
Donor Selection | 1 | 2018 | 232 | 0.140 |
Why?
|
Survival Analysis | 2 | 2021 | 10073 | 0.140 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2021 | 687 | 0.130 |
Why?
|
Cholangitis, Sclerosing | 1 | 2018 | 177 | 0.130 |
Why?
|
beta Catenin | 1 | 2021 | 1039 | 0.130 |
Why?
|
Gene Rearrangement | 1 | 2020 | 1125 | 0.130 |
Why?
|
Azacitidine | 1 | 2017 | 335 | 0.120 |
Why?
|
Biopsy | 5 | 2020 | 6762 | 0.120 |
Why?
|
Actins | 1 | 2022 | 2050 | 0.120 |
Why?
|
Genetic Vectors | 1 | 2024 | 3392 | 0.120 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2017 | 783 | 0.120 |
Why?
|
Metformin | 1 | 2022 | 906 | 0.120 |
Why?
|
Neoplasms | 1 | 2023 | 22131 | 0.110 |
Why?
|
Fatty Liver | 1 | 2020 | 787 | 0.110 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4910 | 0.110 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2020 | 1250 | 0.110 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2872 | 0.110 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1896 | 0.100 |
Why?
|
Microsatellite Instability | 1 | 2016 | 716 | 0.100 |
Why?
|
Vacuoles | 1 | 2012 | 228 | 0.100 |
Why?
|
Liver | 2 | 2018 | 7512 | 0.090 |
Why?
|
Reproducibility of Results | 3 | 2020 | 20074 | 0.090 |
Why?
|
Pancreatitis | 1 | 2018 | 1097 | 0.090 |
Why?
|
Elasticity Imaging Techniques | 1 | 2015 | 391 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2020 | 1653 | 0.090 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1088 | 0.090 |
Why?
|
Young Adult | 5 | 2022 | 59179 | 0.090 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2016 | 1779 | 0.080 |
Why?
|
Tissue Donors | 1 | 2018 | 2331 | 0.080 |
Why?
|
Retrospective Studies | 4 | 2021 | 80566 | 0.080 |
Why?
|
Amyloidosis | 1 | 2015 | 815 | 0.080 |
Why?
|
Hodgkin Disease | 1 | 2016 | 1378 | 0.080 |
Why?
|
Observer Variation | 1 | 2014 | 2606 | 0.080 |
Why?
|
Prognosis | 2 | 2021 | 29600 | 0.070 |
Why?
|
Lung Diseases | 1 | 2018 | 1909 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 3356 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2018 | 2090 | 0.070 |
Why?
|
Liver Diseases | 1 | 2015 | 1297 | 0.070 |
Why?
|
Thyroidectomy | 1 | 2012 | 908 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2024 | 39063 | 0.060 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6807 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 2017 | 2533 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2020 | 3612 | 0.060 |
Why?
|
Adolescent | 3 | 2024 | 88234 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 368 | 0.050 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2023 | 431 | 0.050 |
Why?
|
Heat-Shock Response | 1 | 2022 | 179 | 0.050 |
Why?
|
Hematoxylin | 1 | 2020 | 60 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2020 | 64568 | 0.050 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2020 | 69 | 0.050 |
Why?
|
Blast Crisis | 1 | 2021 | 102 | 0.050 |
Why?
|
Risk Assessment | 2 | 2020 | 23972 | 0.040 |
Why?
|
Esophagoscopy | 1 | 2020 | 397 | 0.040 |
Why?
|
Remission Induction | 1 | 2024 | 2391 | 0.040 |
Why?
|
Heat-Shock Proteins | 1 | 2022 | 795 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 562 | 0.040 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 262 | 0.040 |
Why?
|
Translocation, Genetic | 1 | 2023 | 1392 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15828 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2023 | 1626 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2024 | 915 | 0.030 |
Why?
|
Living Donors | 1 | 2020 | 641 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2024 | 4804 | 0.030 |
Why?
|
Microscopy | 1 | 2020 | 905 | 0.030 |
Why?
|
Child | 4 | 2024 | 80079 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2024 | 2734 | 0.030 |
Why?
|
Abdomen | 1 | 2020 | 1128 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2801 | 0.030 |
Why?
|
Disease Progression | 2 | 2020 | 13495 | 0.030 |
Why?
|
Laser Therapy | 1 | 2020 | 1092 | 0.030 |
Why?
|
Tumor Escape | 1 | 2016 | 371 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8542 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2022 | 1926 | 0.020 |
Why?
|
Risk Factors | 2 | 2016 | 74115 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2821 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1892 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3410 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5239 | 0.020 |
Why?
|
Genotype | 1 | 2024 | 12978 | 0.020 |
Why?
|
Graft Survival | 1 | 2020 | 3820 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 1639 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2017 | 2014 | 0.020 |
Why?
|
Weight Loss | 1 | 2020 | 2682 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7373 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 12758 | 0.020 |
Why?
|
Hospitals | 1 | 2020 | 3877 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2022 | 14389 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16571 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2023 | 10175 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5672 | 0.020 |
Why?
|
Mice | 2 | 2023 | 81368 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12719 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6474 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5780 | 0.020 |
Why?
|
Odds Ratio | 1 | 2016 | 9643 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 3794 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3868 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12447 | 0.010 |
Why?
|
Logistic Models | 1 | 2016 | 13245 | 0.010 |
Why?
|
Animals | 2 | 2023 | 168201 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14648 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16967 | 0.010 |
Why?
|